Chapter 3 Leveraging Resources and Capabilities
(2) The question of imitability—how challenging is it for competitors to imitate valuable and
rare resources/capabilities?
Valuable and rare resources and capabilities can be a source of competitive advantage only if
competitors have a difficult time imitating them. Tangible resources are relatively easy to
imitate, while intangible resources are not. Imitation is difficult because of causal ambiguity,
which refers to the difficulty of identifying the causal determinants of successful firm
performance.
Overall, valuable, rare, but imitable resources and capabilities may give firms some
temporary competitive advantage that leads to above-average performance during some time.
However, such advantage is not likely to be sustainable. Only valuable, rare, and hard-to–
imitate resources and capabilities potentially lead to a sustained competitive advantage.
Teaching Tip: Students can get understandably frustrated with the resource-based, VIRO model
if the instructor merely emphasizes the historical and path-dependent nature of resources. Their
predictable concern, after memorizing the model, is that it doesn’t have practical application.
“Suppose my firm does not have those historical resources? Suppose we do not have reputational
and historical skills (like Hewlett Packard or Disney) that can be used to create competitive
advantage, then what?” Discuss this problem, that is, how can a firm acquire resources and
capabilities, and build new ones? How can a firm spur the creation of a whole new industry, such
as Southwest did with the low-cost, no-frills airline model, or the firm that created the fresh cut
salads in a bag, by developing new and fairly unique competencies and resources (e.g., first
mover-brand names, technological standards, franchising models) in that field?
DEBATES AND EXTENSIONS
______________________________________________________________________________
Teaching Tip: Ask students to consider, perhaps in small groups initially, how a firm such as
Abbott Labs or Pfizer creates and maintains a competitive advantage. Pfizer is more dependent
on a pipeline of patent-protected medicines, while Abbott, in addition to pharmaceuticals, has a